Quantification of Process Induced Disorder in Milled Samples Using Different Analytical Techniques
Open Access
- 16 February 2010
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 2 (1), 30-49
- https://doi.org/10.3390/pharmaceutics2010030
Abstract
The aim of this study was to compare three different analytical methods to detect and quantify the amount of crystalline disorder/ amorphousness in two milled model drugs. X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and Raman spectroscopy were used as analytical methods and indomethacin and simvastatin were chosen as the model compounds. These compounds partly converted from crystalline to disordered forms by milling. Partial least squares regression (PLS) was used to create calibration models for the XRPD and Raman data, which were subsequently used to quantify the milling-induced crystalline disorder/ amorphousness under different process conditions. In the DSC measurements the change in heat capacity at the glass transition was used for quantification. Differently prepared amorphous indomethacin standards (prepared by either melt quench cooling or cryo milling) were compared by principal component analysis (PCA) to account for the fact that the choice of standard ultimately influences the quantification outcome. Finally, the calibration models were built using binary mixtures of crystalline and quench cooled amorphous drug materials. The results imply that the outcome with respect to crystalline disorder for milled drugs depends on the analytical method used and the calibration standard chosen as well as on the drug itself. From the data presented here, it appears that XRPD tends to give a higher percentage of crystalline disorder than Raman spectroscopy and DSC for the same samples. For the samples milled under the harshest milling conditions applied (60 min, sixty 4 mm balls, 25 Hz) a crystalline disorder/ amorphous content of 44.0% (XRPD), 10.8% (Raman spectroscopy) and 17.8% (DSC) were detected for indomethacin. For simvastatin 18.3% (XRPD), 15.5% (Raman spectroscopy) and 0% (DSC, no glass transition) crystalline disorder/ amorphousness were detected.This publication has 27 references indexed in Scilit:
- Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatinEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffractionJournal of Pharmaceutical and Biomedical Analysis, 2009
- Process Induced Disorder in Crystalline Materials:Differentiating Defective Crystals from the Amorphous Form of GriseofulvinJournal of Pharmaceutical Sciences, 2008
- Physicochemical Properties and Stability of Two Differently Prepared Amorphous Forms of SimvastatinCrystal Growth & Design, 2008
- Screening for differences in the amorphous state of indomethacin using multivariate visualizationEuropean Journal of Pharmaceutical Sciences, 2007
- Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1International Journal of Pharmaceutics, 2006
- Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solidsJournal of Pharmaceutical Sciences, 2006
- Current strategies for engineering drug nanoparticlesCurrent Opinion in Colloid & Interface Science, 2004
- X-Ray Powder DiffractometryDrugs and the Pharmaceutical Sciences, 1995
- THE RATE OF SOLUTION OF SOLID SUBSTANCES IN THEIR OWN SOLUTIONS.Journal of the American Chemical Society, 1897